CD52 and graft versus host disease: The knockout of the TCR is intended to reduce the risk of graft-versus-host disease (GVHD) caused by donor T cells, whereas, knockout of the CD52 gene makes transplanted allogenic T cells resistant to the lymphodepleting agent alemtuzumab [240].